Clearside Biomedical, Inc.
CLSDQ evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for CLSDQ—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CLSDQ
Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for retinal diseases via suprachoroidal space (SCS) injection, with one FDA-approved product (XIPERE) and a lead pipeline candidate (CLS-AX) in clinical development.
Key risk: Going concern risk
BioSniper Score
Based on 5 of 6 signals
Market Cap
$1.3M
Cash Runway
4.0 moLead Asset
XIPERE (Approved)Next Catalyst
Patent_Expiry · Apr 16, 2040Financial data as of Sep 30, 2025.
Tracking 1 pipeline candidate · 14 clinical trials · 1 catalyst for Clearside Biomedical, Inc..
Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for retinal diseases via suprachoroidal space (SCS) injection, with one FDA-approved product (XIPERE) and a lead pipeline candidate (CLS-AX) in clinical development.
- XIPERE (triamcinolone acetonide injectable suspension for suprachoroidal use) was approved by the FDA in October 2021 for macular edema associated with uveitis [sec_mda · as of 2025-03-27].
- As of September 30, 2025, the company had an accumulated deficit of $374.0 million and recorded a net loss of $6.0 million for the three months ended September 30, 2025 [sec_mda · as of 2025-11-14].
- Cash and equivalents were $6.8 million as of September 30, 2025, with shareholders' equity of -$38.9 million [sec].
- The company expects to require additional capital to initiate Phase 3 clinical trials of CLS-AX and has expressed substantial doubt about its ability to continue as a going concern [sec_mda · as of 2025-03-27].
- Clearside has primarily financed operations through equity offerings, warrants, convertible notes, and loan agreements, and has not generated product revenue to date [sec_mda · as of 2025-11-14].
What works
- XIPERE is the first FDA-approved therapeutic delivered into the suprachoroidal space (SCS) and the first commercial product developed by Clearside, representing a novel drug delivery platform [sec_mda · as of 2025-03-27].
- The company continues to advance its pipeline, including a planned Phase 3 clinical program for CLS-AX, which targets retinal diseases [sec_mda · as of 2025-05-15].
- Clearside has established intellectual property and regulatory exclusivity for its SCS injection technology, which could provide competitive advantages [sec_mda · as of 2025-05-15].
What to weigh
- The company has an accumulated deficit of $374.0 million as of September 30, 2025, and has incurred net losses since inception, with no product revenue generated to date [sec_mda · as of 2025-11-14].
- Cash and equivalents of $6.8 million as of September 30, 2025, are insufficient to fund operations beyond the near term, and the company has expressed substantial doubt about its ability to continue as a going concern [sec_mda · as of 2025-03-27].
- The successful development and commercialization of CLS-AX or any future product candidates is highly uncertain, with risks including clinical trial enrollment, regulatory approval, and manufacturing [sec_mda · as of 2025-05-15].
- The company relies on external financing (equity, debt, or partnerships) to fund operations, and there is no guarantee that additional capital will be available on acceptable terms [sec_mda · as of 2025-03-27].
From the filings
Quoted directly from source documents.
Accumulated deficit of $374.0 million as of September 30, 2025.
“As of September 30, 2025, we had an accumulated deficit of 374.0 million.”
SEC MD&A · November 14, 2025
Net loss of $6.0 million for the three months ended September 30, 2025.
“We recorded net losses of $6.0 million and $7.7 million for the t”
SEC MD&A · November 14, 2025
Substantial doubt about ability to continue as a going concern.
“These factors raise substantial doubt regarding our ability to continue as”
SEC MD&A · March 27, 2025
Catalyst timeline
- 2040-04-16 · Patent_Expiry · XIPERE — Patent/Exclusivity Expiry: XIPERE — The patent or exclusivity protection for XIPERE is scheduled to expire on this date, which could open the market to generic competition.
Risks & what to watch (4)›
Key risks
- Going concern risk — Cash of $6.8M as of Sep 30, 2025, and substantial doubt about ability to continue as a going concern [sec_mda · as of 2025-03-27].
- No product revenue — Company has not generated product revenue; relies on external financing and license payments [sec_mda · as of 2025-11-14].
- Clinical development uncertainty — Phase 3 trial of CLS-AX requires additional capital; success is highly uncertain [sec_mda · as of 2025-05-15].
- Dilution risk — Future capital raises through equity or convertible securities may dilute existing shareholders [sec_mda · as of 2025-03-27].
What to watch
- Ability to secure additional financing to fund operations beyond Q4 2025 and initiate Phase 3 trials of CLS-AX [sec_mda · as of 2025-03-27].
- Progress and enrollment in the planned Phase 3 clinical program for CLS-AX [sec_mda · as of 2025-05-15].
- Commercialization progress of XIPERE by licensees and any associated milestone payments [sec_mda · as of 2025-11-14].
- Patent/exclusivity expiry for XIPERE on 2040-04-16, which may affect long-term competitive positioning [catalyst].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Clearside Biomedical, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Clearside Biomedical, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
4.0 months
OCF -$5M · Net income -$6M
Lead: Approved
1 candidate
1 upcoming, next in ~4978d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 2.7%
- Days to cover
- 3.9
- Shares short
- 141,010
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CLSDQ short interestGovernance
Frequently asked questions
What is the AI investment thesis for Clearside Biomedical, Inc.?
Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for retinal diseases via suprachoroidal space (SCS) injection, with one FDA-approved product (XIPERE) and a lead pipeline candidate (CLS-AX) in clinical development.
What is Clearside Biomedical, Inc.'s lead drug candidate?
Clearside Biomedical, Inc.'s most advanced tracked candidate is XIPERE (Approved) for Macular edema associated with uveitis.
What is Clearside Biomedical, Inc.'s next catalyst?
Clearside Biomedical, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: XIPERE" — expected April 16, 2040.
Who is the CEO of Clearside Biomedical, Inc.?
Chief Executive Officer is the chief executive officer of Clearside Biomedical, Inc. (CLSDQ).
Where is Clearside Biomedical, Inc. headquartered?
Clearside Biomedical, Inc. (CLSDQ) is headquartered in Alpharetta, GA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.